Clinical Trials
11 trialsNCT02048813 2026-05-29
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02717507 2025-04-23
Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
Children's Oncology Group
Phase 2 Completed
NCT02631746 2025-03-14
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00611351 2023-10-23
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Phase 2 Completed
NCT02670564 2019-04-16
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)
Swiss Pediatric Oncology Group
Phase 4 Unknown
NCT01129193 2018-06-04
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00445744 2018-01-02
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase NA Completed
NCT01212380 2016-05-09
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01126502 2015-11-04
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00769288 2014-01-07
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01316744 2011-05-13
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
National Cancer Institute (NCI)
Phase 3 Unknown